Matthew Spector
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Matthew Spector sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Matthew Spector: 4 sponsored US clinical trials, 3 recruiting.
Matthew Spector sponsors 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pharyngocutaneous Fistula, with 1 trials.
Upper-quartile sponsor footprint
Matthew Spector sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Window of Opportunity in Preserving Laryngeal Function Trial
NCT07423078
Axoguard HA Plus Nerve Protector to Reduce Post-operative Neck and Shoulder Dysfunction in Patients Undergoing Neck Dissection
NCT07283861
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
NCT06831149
Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients
NCT07631650
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Matthew Spector pipeline
3 recruiting of 4 indexed (75% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Pharyngocutaneous Fistula (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Matthew Spector: open-pipeline peers nationwide
Peers matched on 4 registered trials and 75% open enrollment, not the therapeutic-area sidebar.
Matthew Spector sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 75% open enrollment (± trial volume)
- Acepodia Biotech · 75% recruiting · 4 trials
- American Laboratory Products Company · 75% recruiting · 4 trials
- Amryt Pharma · 75% recruiting · 4 trials
- Amydis · 75% recruiting · 4 trials
Related
What to do with this Matthew Spector page
4 registered trials is a research-attention snapshot, not an endorsement of Matthew Spector or any single study.
- 3 of Matthew Spector's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pharyngocutaneous Fistula is the condition Matthew Spector studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pharyngocutaneous Fistula trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Matthew Spector pipeline card: 4 registered trials from official public datasets.Report a data error.